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The filamentous hemagglutinin (FHA) of Bordetella pertussis was expressed in the attenuated aroA mutant of
Salmonella typhimurium, SL3261, and in a strain of Escherichia coli harboring Shigella flexneri plasmid
pWR110, which encodes bacterial invasiveness for epithelial cells. Expression of FHA in these strains did not
interfere with their ability to invade Henle cells. Immunoglobulins A and G specific for FHA were detected in
lung washes of mice following oral immunization with the live recombinant organisms; antibody levels were
significantly higher than those in mice immunized with killed bacteria administered orally or intraperitoneally.
Live oral vaccines carrying protective antigens of B. pertussis may be an important alternative to new-
generation component vaccines against whooping cough.
Bordetella pertussis is the etiological agent of whooping
cough, an infection of the upper and lower respiratory tracts.
The disease is particularly severe in young children and may
lead to neurological disorders and death (45). The incidence
of whooping cough has been largely reduced by mass immu-
nization with a heat-killed, whole-cell vaccine (11). How-
ever, concern about the infrequent but severe neurological
side effects of this vaccine (6, 25) has led to a decreased
acceptance rate (47) accompanied by an increase in disease
incidence (33). New-generation vaccines composed of de-
fined and nontoxic components are urgently needed.
Several virulence factors of B. pertussis have been con-
sidered for inclusion in defined acellular vaccines which
would have reduced toxicity, and studies with animal models
have highlighted pertussis toxoid and filamentous hemagglu-
tinin (FHA) as prime candidates (20, 30). However, acellular
vaccines composed of preparations of these two proteins
exhibited lower efficacy than expected in human trials,
despite their ability to induce a humoral response (1, 26, 43).
A number of vaccines that consist of live microorganisms
which elicit better protection than killed organisms or cell
extracts have been developed. More recently, several atten-
uated mutants of Salmonella spp. have been developed as
delivery systems to stimulate mucosal immunity to cloned
heterologous immunogens (19). These mutants are unable to
multiply extensively or cause disease in the host but do
establish a self-limiting, subclinical infection and can be
detected in tissues such as the liver and spleen (5, 19).
Mucosal, humoral, and cell-mediated immunity to antigens
expressed by these strains can be induced by oral immuni-
zation (3, 9, 10, 19, 29, 35). Such delivery systems are,
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therefore, quite promising for vaccine development, and
recently Salmonella typhi strains and capsule formulations
suitable for oral administration have been accepted by the
U.S. Food and Drug Administration for human use (22).
A related antigen delivery system is Escherichia coli K-12
containing the virulence plasmid pWR110 of Shigella flex-
neri, which specifies bacterial invasion of mammalian cells
(16, 17, 23, 39, 40). This bacterium invades HeLa cells in
tissue culture and produces a mild inflammatory reaction in
the lamina propria in the rabbit ileal loop test (38). Monkeys
orally immunized with E. coli K-12(pWR110) expressing S.
flexneri 2a surface antigens were protected against oral
challenge with virulent S. flexneri 2a bacteria (12).
Here we describe the oral immunization of mice with
Salmonella typhimurium aroA and invasive E. coli hybrids
expressing the 220-kDa FHA of B. pertussis and the induc-
tion of both systemic immunoglobulin G (IgG) and mucosal
IgA anti-FHA antibodies.
MATERIALS AND METHODS
Bacterial strains, plasmids, and media. The bacterial
strains used in this work were E. coli EC538 (J. E. G.
McCarthy), S. typhimurium aroA SL3261 (19), and E. coli
K-12 strain 395-1 (38). The plasmids used in this work were
pCG26 (Apr) (15), pWR110 (Km), and R64drdll (Tcr) (17,
38, 39).
E. coli and S. typhimurium strains were grown in Luria
broth or on Luria agar plates (36). B. pertussis was grown on
Bordet Gengou agar base (Difco) supplement with 1% glyc-
erol and 15% (vol/vol) defibrinated horse blood or SS-X
broth (42). Antibiotics were used at the following concentra-
tions: ampicillin, 100 p.g/ml; tetracycline, 50 pxg/ml; and
kanamycin, 50 ,ug/ml. Broth cultures were aereated by
shaking at 200 rpm in a New Brunswick Environmental
Incubator Shaker.
Induction experiments. These experiments were per-
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formed as previously described (15). Protein concentrations
of samples were determined by the Lowry procedure as
modified by Sanderman and Strominger (37).
Tissue culture methods and in vitro determination of adhe-
siveness and invasiveness. The human intestinal epithelial cell
line Henle 407 (ATCC CCL-6) was maintained in Dulbecco's
modified Eagle medium (DME; GIBCO Laboratories, Egg-
enstein, Germany) with 10% fetal calf serum (FCS)
(GIBCO)-5 mM glutamine (Flow Laboratories Inc., Mclean,
Va.)-1 mM pyruvate (Flow) in an atmosphere containing 5%
CO2 at 37°C. Trypsinized cells were seeded at a concentra-
tion of approximately 2 x 105 cells per coverslip (15 by 15
mm) in tissue culture plates (12 by 4.5 cm2; Flow). These
were incubated for 18 to 24 h and washed three times in
phosphate-buffered saline (PBS; NaCI [8.0 g liter-'], KCl
[2.0 g liter-1], Na2HPO4 2H20 [2.0 g liter-'], KH2PO4 [2.0
g liter-1]) (pH 7.4). For infection of monolayers, bacteria
were harvested in the exponential growth phase by centrif-
ugation, resuspended to a density of 108 CFU/ml in DME,
overlaid onto the monolayer of cells on a coverslip, and
incubated for 30 min at 37°C with 5% CO2. Unattached and
loosely attached bacteria were removed by washing the
monolayers three times with PBS. For adhesiveness assays,
the monolayers were then stained with Giemsa solution and
examined by light microscopy, and the mean number of
bacteria per Henle cell was calculated by averaging the
number of bacteria adhering to 40 cells. For invasiveness
assays, DME containing gentamicin (100 ,ug/ml) was then
added; this concentration of gentamicin killed extracellular
bacteria and thereby prevented any reinfection of cells.
Monolayers were incubated for an additional 3 h and then
washed three times with PBS. The number of invading
bacteria was determined both by selectively staining the
viable intracellular microorganisms by using the method
described by Pruzanski et al. (32) and by lysing the eukary-
otic cells with 1 ml of ice-cold water added to each well and
then determining the viable count on Luria agar plates.
DNA manipulations. Plasmid DNA isolation and transfor-
mation were performed as described by Sambrook et al. (36).
Conjugal transfer of pWR11O (Kmr) to E. coli EC538 was
accomplished with the mobilizing helper plasmid R64drdll
(Tcr), as previously described by Sansonetti et al. (38, 39).
Mouse immunization. Six- to seven-week-old female
BALB/c mice were immunized and caged separately. Mice
were immunized as shown in Table 1. Groups a to i were
immunized with one dose on day 0 and boosted with an
identical dose 24 days later. The animals were sacrificed 10
days after the booster, and the samples were collected. For
groups j and k, only 1 dose was given, and the mice were
sacrificed 24 days later. For peroral immunization, an over-
night broth culture of bacteria was diluted 100-fold with
Luria broth containing an appropriate antibiotic for selection
and the fresh culture was incubated at 37°C until it reached
early logarithmic phase. The cultures were centrifuged, and
the bacteria were resuspended in PBS to an appropriate
optical density to give the desired viable count as determined
previously for each strain. Immediately before immuniza-
tion, an equal volume of 3% sodium bicarbonate in PBS (pH
8.0) was added to the suspension. Mice that had been
deprived of water for 6 to 8 h were then gently fed with 50 pul
of the bacterial suspensions. For immunization with heat-
killed bacteria, bacterial suspensions in PBS were treated at
60°C for 30 min. Sacrificed mice were exsanguinated by
cutting the brachial artery, and the collected sera were
separated and stored at -20°C. Lung washes were collected
by pertracheal cannulation and gentle washing with 0.7 ml of
TABLE 1. Mouse immunization protocols
Groupa Strain Nmicef Dose Route Viability
a SL3261 6 109 Oral Live
b SL3261(pCG26) 6 109 Oral Heat killed
cb SL3261(pCG26) 5 109 Oral Live
d SL3261(pCG26) 6 106 i.p. Live
e EC538(pCG26) 6 109 Oral Live
f6 EC538(pCG26, 6 109 Oral Live
pWR110)
g B. pertussis Tohama 6 106 i.p. Heat killed
h SL3261 6 106 i.p. Heat killed
i SL3261(pCG26) 6 106 i.p. Heat killed
j SL3261(pCG26) 5 109 Oral Live
k EC538(pCG26, 5 109 Oral Live
pWR110)
Groups a to i were immunized twice (days 0 and 24) and sacrificed 10 days
after the booster; groups j and k were immunized once and sacrificed 24 days
later.
b Experiments with these groups were repeated with independently pre-
pared vaccines and the same number of mice (five and six, respectively).
Results in Fig. 2 refer to averages from both experiments.
ice-cold PBS containing 2 mM phenylmethylsulfonylfluoride
as the protease inhibitor. About 0.5 ml of lung wash was
recovered from each mouse, centrifuged at 4°C at 3,000 x g
for 5 min to remove debris, and stored at -20°C.
Immunological techniques. Monoclonal antibody P12H3
against FHA was kindly provided by C. Parker (13). For
Western blot experiments, whole-cell extracts of bacteria
were mixed with loading buffer (36) in a ratio of 1:1, and
approximately 50 ,ug of protein was electrophoresed accord-
ing to the procedure of Laemmli (21) by using a 3.85%
acrylamide stacking gel and a 10% acrylamide separating gel.
Blotting was carried out essentially as described by Burnette
(4). Proteins were transferred to a nitrocellulose membrane
with a semidry transfer cell by using 25 mM Tris-192 mM
glycine-20% methanol, pH 8.3, as the transfer buffer and a
10% solution of0.3% fat milk in PBS, pH 7.4, as the blocking
reagent. The blocked membrane was incubated for 2 h with
the first antibody (hybridoma P12H3 supernatants diluted
1:20 in PBS), washed three times with PBS, and incubated
for 1 h with Bio-Rad horseradish peroxidase-conjugated goat
anti-mouse IgG. Membranes were washed and developed
with 4-chloro-1-naphthol as a substrate. Prestained molecu-
lar weight markers were purchased from Bio-Rad.
For the determination of subclass-specific antibodies
against FHA in serum and lung washes, enzyme-linked
immunosorbent assays (ELISA) were performed as follows.
Nunc Maxisorp Immunomodule 96-well plates were coated
with FHA purified from B. pertussis Tohama by the proce-
dure of Sato et al. (41) and diluted in 0.1 M NaHCO3 (pH 9.6;
60 ng in 50 ,u per well; incubation at 4°C overnight). The
wells were blocked with 100 pL of 10% FCS in PBS for 2 h at
37°C. Plates were subsequently washed three times with
PBS, and 100 ,lI of serum samples diluted 1:25 or lung
washes diluted 1:10 in 10% FCS in PBS was added to each
well. After 60 min at 37°C, the plates were washed again and
100 pul of peroxidase-conjugated goat anti-mouse antibodies
for IgG (Fc), IgM (Jackson Immunoresearch Laboratories),
or IgA (Southern Biotechnology Associates, Inc.) heavy
chains diluted 1:1,000 in 10% FCS in PBS was added to each
well and incubated 1 h at 37°C. The plates were washed again
and developed by the addition of 200 ,ul of activated sub-
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FIG. 1. Expression of nonfusion FHA in E. coli and S. typhimu-
rium aroA. Total cell extracts were analyzed by Western blot by
using P12H3 monoclonal antibody. Lanes: 1, molecular mass stan-
dards; 2 and 4, S. typhimurium aroA SL3261 containing pCG26; 3
and 5, E. coli EC538 containing pCG26 and pWR110; 6, B. pertussis
Tohama. Expression was not induced by growth at 30°C (lanes 2 and
3) or induced for 3 h at 37°C (lanes 4 and 5). The molecular masses
of the standards in kilodaltons are indicated.
strate solution (0.025 M citric acid, 0.05 M Na2HPO4,
0.015% H202, 0.3 g of o-phenyldiamine dihydrochloride
liter-1) per well. After 30 min at room temperature, the
reaction was stopped by the addition of 50 pd of 0.25 M
H2SO4 and the A490 was determined with a Bio-Rad 3550
microplate reader. All samples were processed simulta-
neously on the same day, normal nonimmunized mouse
serum or lung wash was used as the blank for the ELISA
readings, and each mouse serum or lung wash was individ-
ually assayed; standard deviations represent variations be-
tween individual mouse samples in each group.
RESULTS
Expression of recombinant nonfusion FHA in S. typhimu-
rium and E. coli. The construction of recombinant S. typhi-
murium aroA SL3261(pCG26) and E. coli EC538(pCG26)
strains was described previously (15). In these strains,
nonfusion recombinant FHA (200 to 220 kDa) is either
produced as a soluble cytoplasmic protein (EC538) or de-
posited in inclusion bodies (SL3261). The wild-type and the
recombinant protein have similar migration patterns on
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE).
The pWR11O (Kmr) 140-MDa virulence plasmid encoding
the invasive phenotype of S. flexneri was mobilized into
EC538(pCG26) (Apr) by using the helper plasmid R64drdll
(Tcr) and selecting for Apr Kmr transconjugants to produce
EC538(pCG26, pWR110). In both recombinant strains,
SL3261(pCG26) and EC538(pCG26, pWR110), the FHA
gene is under the control of the thermoregulated tandem PR
and PL promoters and the translation initiation region of the
E. coli atpE gene. The first 15 codons of the FHA gene had
been engineered to reduce mRNA secondary structure in the
NH2-terminal coding region. Expression is repressed at 30°C
and induced at temperatures above 34°C. Western blot
analysis (Fig. 1) demonstrated that in both SL3261 and
TABLE 2. In vitro adhesiveness and invasiveness of strains
used in the vaccination protocols
Invasiveness
Strain Adhesivenessa %
Infected cells' CFUc
SL3261 13.3 ± 6.3 11 1.5 x 103
SL3261(pCG26) 12.1 ± 5 12 1.2 x 103
EC538(pCG26) 2.8 ± 1.8 2 <25d
EC538(pCG26, 63.8 ± 9.9 98 7 x 104
pWR110)
E. coli K-12 395-1 58.3 ± 10.7 95 5 x 104
(pWR110)
EC538 1.7 ± 1.8 3 <25d
" Mean number of attached bacteria per Henle cell ± the standard devia-
tion.
b Percentage of Henle cells invaded by at least five bacteria.
'CFU of viable intracellular bacteria per coverslip.
d Limit of detection.
EC538(pWR110) carrying pCG26, FHA is efficiently ex-
pressed at 37°C (lanes 4 and 5) and efficiently repressed at
30°C (lanes 2 and 3). Expression in the recombinants was
higher than in wild-type B. pertussis Tohama (lane 6);
extensive degradation was observed in all strains, although
this may not be important for vaccine purposes. The pres-
ence of pWR110 did not significantly interfere with FHA
expression. Cultures of SL3261(pCG26) and EC538(pCG26,
pWR110) were grown overnight in Luria broth without
antibiotics, and dilutions were spread onto Luria agar plates
with and without antibiotics. The presence of antibiotic had
no significant effect on the number of CFU obtained (data
not shown), thus demonstrating reasonable stability of the
hybrid plasmid in these host bacteria.
In vitro adhesiveness and invasiveness of strains used in the
vaccination protocols. The results presented in Table 2 show
that the presence of hybrid plasmid pCG26 did not alter the
adhesive or invasive properties of the carrier strains. E. coli
harboring pWR110 adhered more efficiently to Henle cells
than did the Salmonella strain, which in turn adhered more
efficiently than E. coli lacking pWR110. The two methods
used to assess invasiveness gave comparable results. No
viable bacteria were isolated from invasion assays with E.
coli lacking pWR110, and the few Henle cells observed
microscopically to contain such bacteria may be artifacts. E.
coli bacteria containing plasmid pWR110 were considerably
more invasive than Salmonella bacteria. This is probably
due at least in part to the inability of S. typhimurium to
replicate in vivo as a result of its aroA mutation. However,
the invasiveness of S. typhimurium was considerably greater
when centrifugation was used to facilitate contact between
bacteria and host cells (results not shown). The relevance of
this to the in vivo situation is not, however, clear.
Antibody responses specific for B. pertussis FHA in vacci-
nated mice. Both FHA delivery systems elicited specific
serum and mucosal immune responses (Fig. 2). Some corre-
lation between the ability of carrier strains to invade Henle
cells in vitro and their ability to stimulate antibody produc-
tion in the lungs was observed. Higher immune responses
from live vaccines are evident from a comparison of the
immune responses induced by intraperitoneal (i.p.) immuni-
zation (compare group d with groups g and i in Table 1 and
Fig. 2) and peroral immunization (compare groups b and c in
Table 1 and Fig. 2). Moreover, IgA could be detected in the
lungs only when the peroral route was used for delivering S.
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FIG. 2. Levels of specific antibodies in sera (A) and lungs (B) after immunization of mice. Standard deviations are indicated by vertical
lines. IP, intraperitoneal.
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typhimurium aroA or invasive E. coli live vaccines (compare
groups c and f with groups b and d in Table 1 and Fig. 2B).
After i.p. immunization with live SL3261(pCG26), FHA-
specific IgG, but no IgA, was detected in serum and lung
washes (IgG can diffuse from blood to the lower respiratory
tract). The serum or lung wash samples in which specific
immunoglobulins could be detected by ELISA also reacted
with purified FHA in Western blots (data not shown).
The invasion plasmid pWR110 was essential for antibody
induction (compare groups e and f in Fig. 2). Two doses of
peroral immunization were necessary for the induction of
good antibody titers: only one dose of either SL3261(pCG26)
or EC538(pCG26, pWR110) (groups j and k) resulted in IgG
serum ELISA readings of 0.15 for group j and 0.10 for group
k and IgA lung wash readings of 0.03 for both j and k.
Significant specific IgM was not detected in lung washes
after any immunization, but very low levels could be de-
tected in serum after either oral immunization with
SL3261(pCG26) or EC538(pCG26, pWR110) or i.p. immuni-
zation with B. pertussis.
DISCUSSION
Whooping cough is a disease with a respiratory tract portal
of entry. To prevent infection, it is desirable to develop
vaccines which stimulate not only specific serum antibodies
but also specific IgA in the respiratory tract. Such secretory
antibodies may interfere with the early events of bacterial
attachment and colonization. The prevention of infectiQn as
well as disease is important if vaccines are to facilitate
eradication of a disease for which there is only a human
reservoir. From serological studies in patients with pertussis
(44), increases in IgG and IgA against different virulence
factors of B. pertussis were observed, whereas whole-cell-
vaccinated individuals gave very weak, if any, increases in
IgA titers.
The presence of specialized cells associated with the
uptake of macromolecules in the gut (28) and the mucosal
immunological network with subpopulations of lymphoid
cells that can migrate from the intestine to other distant
mucosae (e.g., the respiratory tract) (2, 24, 34), together with
the experimental evidence of immune responses in serum
and salivary glands after peroral immunization (7), indicate
that live peroral vaccines may be good candidates for
whooping cough. Our data clearly support the usefulness of
this approach. Oral immunization of mice with live S.
typhimurium aroA and invasive E. coli expressing B. pertus-
sis FHA induced both serum IgG and secretory IgA antibody
responses in the lungs.
Delivery systems based on E. coli(pWR110) offer more
flexibility than Salmonella systems. The genetics of S.
typhimurium is not as well developed as that of E. coli, and
it is easier to optimize expression of recombinant antigens in
E. coli and then transfer in the necessary invasion genes.
Although we were fortunate in obtaining good expression of
FHA in the one Salmonella strain selected, we found expres-
sion in E. coli to be highly strain dependent (15). Obviously,
plasmids such as pWR110 which specify antibiotic resistance
are unacceptable in human vaccines, but the existence of
versatile transposon cloning vectors lacking antibiotic resis-
tance markers that can stably integrate cloned genes into
host chromosomes (18) will enable the cloning of invasion
genes (23) and their insertion into the chromosomes of
selected antigen carrier strains. The stability of immunogen-
coding sequences and the absence of antibiotic resistance
selection markers are crucial features of live vaccines. To
achieve these goals, we are currently working on transpo-
son-mediated chromosomal integration (18) of the FHA gene
and the necessary expression signals needed to achieve
high-level in vivo expression of FHA, by using an approach
that previously gave good expression of the pertussis toxin
operon in Bordetella bronchiseptica (46).
Recently, Parker and coworkers (27, 31) orally immunized
mice with Salmonella bacteria expressing truncated FHA by
using a host-vector system which causes release of the
intracellular antigen and prevents loss of hybrid plasmids in
vivo. Although this group was able to detect FHA-specific
IgG in serum, they failed to detect specific IgA in lung
washes. The strong mucosal immune responses measured in
our experiments may be due either to a higher level of
expression of FHA in pCG26-carrying bacteria or to the
particular delivery strains used in this study. In addition,
pCG26 specifies the entire 220-kDa protein, and it is possible
that the native protein is more immunogenic than the trun-
cated forms expressed in previous studies (27, 31).
The role of cell-mediated immunity in protection against
B. pertussis is not known, although a cell-mediated response
to several B. pertussis antigens, including FHA, has been
demonstrated in convalescent patients (8, 14). As Salmonel-
la-expressing heterologous antigens are known to induce
cell-mediated immunity (3, 35), it will be of interest to
determine whether the delivery systems used in this study
induce cell-mediated mucosal responses to FHA in addition
to an antibody response.
It is not known whether vaccines based solely on FHA can
offer sufficient protection in humans against B. pertussis
infection (26, 43, 44). However, the potential of these carrier
systems to stimulate a strong mucosal immune response to
B. pertussis antigens that we demonstrate here will encour-
age the construction of carrier strains expressing more than
one B. pertussis antigen. The recent successful oral immu-
nization against tetanus in mice by using the SL3261 carrier
strain (10) supports this thesis and opens up new perspec-
tives for the development of oral attenuated multivalent
vaccines that could replace the old DTP vaccine in vaccina-
tion regimens.
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